Biohaven (BHVN) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Xencor (XNCR) has outperformed Biohaven (BHVN) over the past year, gaining 88.6% versus a loss of 29.9%. Xencor is the larger company by market cap ($1.83 billion vs $1.82 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | XNCR |
|---|---|---|
| Share price | $12.08 | $24.63 |
| Market cap | $1.82B | $1.83B |
| 1-day change | +1.26% | +0.53% |
| YTD return | +7.00% | +60.88% |
| 1-year return | -29.89% | +88.59% |
| 5-year return | — | -35.98% |
| EPS (TTM) | $-4.62 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $125.58M |
| Revenue growth (YoY) | — | +13.65% |
| Net income (latest FY) | $-738.82M | $-91.92M |
| Operating margin | — | -141.35% |
| Net margin | — | -73.20% |
| 52-week high | $18.57 | $30.61 |
| 52-week low | $7.48 | $10.38 |
| Distance from 52-week high | -34.93% | -19.54% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +76.08% | +27.57% |
| Average volume | 2.63M | 1.32M |
| Shares outstanding | 151.04M | 74.35M |
| Employees | 274 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed BHVN by 118.5 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
BHVN vs XNCR FAQ
Which is bigger, Biohaven or Xencor?
Xencor (XNCR) is larger, with a market capitalization of $1.83B compared with $1.82B for Biohaven (BHVN).
Which stock has performed better over the past year, BHVN or XNCR?
XNCR returned +88.59% over the past 12 months, compared with -29.89% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.